DISCLOSURES

This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea





DISCLOSURES

COMPLETING THIS ACTIVITY

Successful completion of this continuing education activity includes the following:

- Attending the entire CE activity;
- Completing the online evaluation;
- Submitting an online CE request.

Your certificate will be sent via email If you have any questions about this CE activity, contact Michelle Daugherty at mdaugherty@cardeaservices.org or (206) 447-9538



DISCLOSURES

Faculty: Jonathan Owen, PharmD & Neelam Gazarian, PharmD

<u>CME Committee</u>: David Couch; Kathleen Clanon, MD; Johanna Rosenthal, MPH; Pat Blackburn, MPH; Richard Fischer, MD; Sharon Adler, MD

<u>CNE Committee</u>: David Stephens, BSN, RN; Erin Edelbrock MPA; Ginny Cassidy-Brinn MSN, ARNP; Carolyn Crisp, MPH



CONFLICT OF INTEREST

Richard Fischer, MD is a member of an Organon speaker's bureau.

Dr. Fischer does not participate in planning in which he has a conflict of interest, and he ensures that any content or speakers he suggests will be free of commercial bias.

None of the other planners or presenters of this CE activity have disclosed any conflict of interest including no relevant financial relationships with any commercial companies pertaining to this CE activity.



Acknowledgement

This presentation is funded in part by:

The Indian Health Service HIV/AIDS & Hep C Program and
The Secretary's Minority AIDS Initiative Fund

There is no commercial support for this presentation



Outcomes and Objectives:

Conference Objective: At the completion of this activity, the learner will be able to explain the steps that would be necessary to begin to screen for and treat patients with the Hepatitis C Virus (HCV) at their practice sites.

By the end of this learning event participants will be able to:

 Describe tools for management of the care of HCV patients and how to implement them



Starting a HCV Treatment Program-Belcourt

Authored and Presented by: LCDR Jonathan Owen, PharmD

LT Neelam Gazarian, MS, PharmD

Quentin N. Burdick Memorial Health Care Facility

Indian Health Service

Belcourt, ND

12/14/2017

Agenda

- Describe use of tools to manage complex care of hepatitis C patients, discuss workload capabilities.
- Share resources of NICE Project with participants to help manage hepatitis C clinic.





Who are we?





Prior to HCV Clinic

With Insurance (Pvt./Federal)

Referred to Medical Specialists

\$10,000-\$15000/referral

Distance Lost to follow-up Without Insurance

Very Few Options

Rationing Care

Poor outcomes

Inter-collaborative Approach



Identifying Patients with Hepatitis C

iCare

168 patients

• 25% screening rate

VGEN

155 patients

EHR Documentation

Referral

Consult
from PCP

Walk in

Initial Visit

PHQ-9 AUDIT-C

Education

Labs

Immunizations

Comprehensive visit

Project ECHO

Start Medication Authorization Treatment

Counseling

Labs

Immunizations

End of Treatment

Labs

SVR

Patient is cured!

Counsel about re-infection and prevention


Consult Template



EHR Note Templates

```
HCV Treatment Program: Initial Visit with Patient
HCV Treatment Program: Comprehensive Visit with Patient
HCV Treatment Program: Initiation of Treatment Visit with Patient
HCV Treatment Program: Continuation of Treatment Visit with Patient
HCV Treatment Program: End of Treatment Visit with Patient
HCV Treatment Program: Three Months Post Completion of Treatment
```

EHR Note Templates



Hepatitis C Labs Order Menu

HEPATITIS C LAB PANEL

Hep C Screen

IF POSITIVE OR KNOWN HISTORY OF HCV DO

HCV RNA QT REFLEX GENOTYPE

Hep C PCR QUANT

Lab values required within past 3 months

Chem 14

CBC/Auto Diff

Fibrotest

PT/INR

Anemia Panel

Vitamin D

Alpha Fetoprotein Tumor Marker

HIV Screen

Hepatitis A Total Antibody

Hepatitis B Surface Antibody

Hepatitis B Core Antibody

Hepatitis B Surface Antigen

Must have at least 2 UDS in last 12 months

at least 3 months apart

Urine Drug Screen

Pregnancy Test


Hepatitis C Order Set Initial Tests

Hepatitis C 4 week ETR and SVR labs


Hepatitis C 8 week labs

All other labs

Hepatitis C Labs Order Set



Patient Management Tools



Managing Patients

Excel document for patient management

Created by Jessica Leston, Brigg Reilley, and David Stephens

Automatically calculates APRI, FIB 4 scores

Excellent for helping to prioritize patients based on liver function and viral load

Managing Patients

New panel created by Nelly to help manage patients referred to the clinic

Spin-off of previous panel, automatically calculates APRI, FIB 4 scores

Organized by stage in the treatment processes

Reminders for labs while in treatment, immunizations, notes

Managing Patients

Snapshot of stage in treatment process drop down menus (these can be adjusted)

White: Unable to contact

Green Ready to present to ECHO

Blue Started treatment

Yellow Pending Appt need labs

Red UDS Positive

Purple Medication Approval Pending

Orange Completed treatment, pending SVR labs

Grey CURED

Patient Panel

12/12/1986 CURED

7778

98686

8587

78456

32625

1/18/1955 Cannot contact

9/8/1998 Ready to present to ECHO

12/21/1949 Ready to present to ECHO

1/22/1961 Pending Appt need labs

8/7/1965 Medication Approval Pending

NORTHERN TIER INITIATIVE for BLIMINATION

loe,b

loe,c

loe,d

loe,e

loe,f

NICE Project- Northern Tier Initiative for Hep C Elimination

Hepatitis C Patient Panel List Developed by: LT Neelam 'Nelly' Gazarian, PharmD. QNBMHCF, Belcourt ND

with LCDR Jonathan Owen, PharmD. email: neelam.gazarian@ihs.gov, jonathan.owen@ihs.gov

NICE Project- Northern Tier Initiative for Hep C **Hepatitis C Patient Panel List**

Developed by: LT Neelam 'Nelly' Gazarian, Pharm with LCDR Jonathan Owen, PharmD.

>0.7 APRHikely

fibrosis or cirrhosis

#DIV/0!

0.52173913

4.134615385

1.164215686

0.895522388

#DIV/0!

#DIV/0!

#DIV/0!

#DIV/0!

2.91755945

1.9772025

3 2.52982213

#DIV/0!

1 1.76079263

#DIV/0!

#DIV/0!

15000

120000

no ins

expan

no ins

medio

Expan

Expan

Sheet19!A1

Sheet20!A1

Sheet22!A1

Sheet23!A1

email: neelam.gazarian@ihs.gov, jonathan.owen@ihs >3.25 likely advanced fibrosis, < 1.45 unlikely advanced fibrosis

| | | | | | Date IOI MEXT | | | | TIDIOSIS OF ORTHOSIS | | CI. TO GI IIIKCIY | aaranocanbiosis | | | | |
|--------------|-------|-----------|---------------------------------------|-------------|---------------|----------|----------|-----------|----------------------|------------|-------------------|------------------|------------|-----------|--------------|---------|
| atient Name | ID | DOB | Patient Status | Age in 2017 | Appt | AST/SGOT | ALT SGPT | Platelets | APRI | APRI Stage | FIB 4 | FIB 4 Stage Calo | Viral Load | Genotype | Labs ordered | Notes |
| mith,Jane | 12345 | 3/3/1986 | Pending Appt need labs | 31 | 10/2/2017 | 140 | 180 | 250 | 1.4 | 3 | 1.293938 | 1 | 3800000 | 1a | Sheet1!A1 | HARVO |
| mith,s | 12346 | 1/1/1961 | Already started treatment | 56 | 11/5/2017 | 48 | 48 | 299 | 0.401337793 | 1 | 1.2975899 | 1 | 4100000 | 1a or 1b | Sheet2!E2 | FO, Exp |
| loe,j | 12347 | 1/2/1981 | May need Beh Health Consult | 36 | 10/7/2017 | 42 | 60 | 348 | 0.301724138 | 1 | 0.56091483 | 1 | 200 | unknown | Sheet3!A1 | Medic |
| loe,john | 12348 | 1/3/1977 | Pending Appt need labs | 40 | 10/2/2017 | 28 | 36 | 297 | 0.235690236 | 1 | 0.6285073 | 1 | 18000000 | 2b | Sheet4!A1 | Expan |
| mith,m | 123 | 1/4/1987 | Ready to present to ECHO | 30 | 10/13/2017 | 30 | 41 | 239 | 0.313807531 | 1 | 0.58810203 | 1 | 200 | | Sheet5!A1 | Expan |
| mith,a | 1234 | 1/5/2015 | Pending Appt need labs | 2 | 11/14/2017 | 484 | 624 | 223 | 5.426008969 | 3 | 0.17377136 | 1 | 370000 | 1a or 1b | Sheet6!A1 | Medic |
| mith,b | 111 | 1/6/1933 | Purple Medication Approval Pending | 84 | 10/15/2017 | 96 | 104 | 169 | 1.420118343 | 3 | 4.67893643 | 3 | 3 | 1a or 1b | Sheet7!A1 | |
| mith,c | 1112 | 1/7/1945 | Ready to present to ECHO | 72 | 11/16/2017 | 50 | 70 | 333.5 | 0.374812594 | 1 | 1.2902018 | 1 | 430000 | 1a | Sheet8!A1 | echo 9 |
| mith,d | 1549 | 1/8/1965 | Already started treatment | 52 | 10/17/2017 | 34 | 31 | 195.6 | 0.434560327 | 1 | 1.62342625 | 3 | 2600 | 1 | Sheet9!A1 | Medic |
| luck,donald | 1456 | 2/8/2017 | Medication Approval Pending | 0 | 9/26/2017 | 55 | 41 | 277 | 0.496389892 | 1 | 0 | 1 | 920000 | 1a or 1 b | Sheet10!A1 | |
| Nouse,Mickey | 78946 | 8/15/1955 | Already started treatment | 62 | 8/1/2017 | 38 | 42 | 177 | 0.536723164 | 1 | 2.05389092 | 3 | 9200000 | 2b | Sheet11!A1 | 2b EP0 |
| nouse,Minnie | 4568 | 8/8/1999 | Pending Appt need labs | 18 | | 105 | 133 | 212 | 1.238207547 | 3 | 0.77303672 | 1 | L | | Sheet12!A1 | Expan |
| an,peter | 45566 | 1/12/1966 | Already started treatment | 51 | | 43 | 56 | 345 | 0.311594203 | 1 | 0.84942595 | 1 | 4400000 | 1 | Sheet13!A1 | 1a or |
| oppins,Mary | 4848 | 5/9/1988 | Completed treatment, pending SVR labs | 29 | | 47 | 67 | 211 | 0.556872038 | 1 | 0.78917987 | 1 | L | #REF! | Sheet14!A1 | Harvo |
| Vonka,Willy | 89621 | 5/9/1944 | Cannot contact | 73 | | | 37 | | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | | #REF! | Sheet15!A1 | no ins |
| ree,Willy | 4576 | 3/8/1992 | May need Beh Health Consult | 25 | | 50 | 110 | 244 | 0.512295082 | 1 | 0.4884542 | 1 | 4000000 | 3 | Sheet16!A1 | medic |
| loe,a | 4562 | 5/9/1985 | Pending Appt need labs | 32 | | 88 | 216 | 314.5 | 0.699523052 | 1 | 0.60923539 | 1 | 3600 | 3 | Sheet17!A1 | expan |
| | | | | | | | | | | | | | | | | |

129

54

116

90

230

Date for Next

30

62

19

52

67

56

Individual Patient Data

| | IIIUI | viuud | al rat | וכוונ של | ala | | | | | | | | |
|---------------|-----------------|--------------|---------------------|--------------------------|---------------------|------------------|----------|---------|-----------------|------------------|-----------------|-----------|--|
| | | | | | D-t- H- | Date Hep A | | D | | Date 3rd | Date Twinrix | Twinrix | Twir |
| | Labs to Order | Date Ordered | Select | from Menu | Date Hep Shot 1s | | 0 wee | Hep B | Shot 1 month | Shot 6 months | Shot | 2nd shot | 3rd s |
| | HCV Screen | Date Gracica | 50,000 | TOTAL MICHAEL | Shot 13 | 6/28/1900 | | -K | | 6/28/1900 | | 1/28/1900 | |
| $\overline{}$ | HCV Viral Load | | Pick from drop down | | + | 0/20/2500 | 1 | • | 1/20/1500 | 0/20/2500 | A | 1/20/1300 | 3/2// |
| , | HCV GT | 11/20/2017 | | | | | | | | | | | |
| | NS5A Resistance | | . | | Enter Date | | Enter | Date | | | Enter Date | | |
| ~ | Pregnancy Test | 11/20/2017 | Negative | | MM/DD/Y | | _ | DD/YYYY | | | MM/DD/Y | | |
| <u>~</u> | HIV Screen | 11/20/2017 | | < Pick from drop down | | | | _ | | | | | |
| | Chem 14 | | | | | | | | | | | | |
| | СВС | | | | | | | | | | | | |
| | PT/INR | | | Hep B Ab/Shot , If no | | | | | | | | | |
| | Anemia Panel | | Hep A serology/shot | please give shot and f/u | | | | | | | | | |
| | Vit D | | Pick from drop down | for series | | | | | | | | | |
| | AFP Marker | | | Pick from drop down | | | | | | | | | |
| | Fibrotest | | + | | | | | | | | | | |
| | Hep A Ab | | | + | | | | | | | | | |
| | Hep B s Ab | | | | | | | | | | | | |
| | Hep B s Ag | | | | | | | | | | | | |
| | Hep B core Ab | | | | | | | | | | | | |
| | UDS | | | < Pick from drop down | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | Enter Date> | | | | | | | | | | | |
| | | MM/DD/YYYY | | Treatment Start Date | HCV KIN | A Results | | | ng Patients | | | | |
| _ | At 4 week | | 1/28/1900 | At 4 week | | ▼ Pick from | n drop o | down | | | | | |
| | HCV Viral Load | | | | | der 8 week Labs | _ | | | | | | |
| | Chem 14 | | | | 01 | rder 8 week Labs | | | | | | | |
| | CBC | | | | | | _ | | | | | | |
| | | | - / / | | | | <u> </u> | | | | | | |
| | At 8 weeks | | 2/25/1900 | At 8 weeks | | < Pick fron | n drop o | down | | | | | |
| | HCV Viral Load | | | | | | | | | | | | |
| | Chem 14 CBC | | | | | | | | | | | | |
| | CBC | | | | | | | | | | | | |
| | At ETR | | 2/24/4000 | A+ ETD | | < Pick from | dese | dowe | | | | | |
| | HCV Viral Load | | 3/24/1900 | ALEIN | | K PICK from | arop | uown | | | | | - |
| - | Chem 14 | | | | | | | | | | | | |
| | CBC | | | | | | | | | | | | |
| | 000 | | | | | | | | | | | | |
| | At SVR | | 6/16/1900 | A+ SVR | | < Pick from | drop (| down | | | | | |
| | HCV Viral Load | | 0/10/1900 | AL VIII | | V PICK ITOI | u op t | GOWII | | | | | |
| | Chem 14 | | | | | | | | | | | | |
| - | Critini 14 | | | | | | | | | | | | |

Appointment Calendar

| OCTO | BER | NUTE: | | ENTER MONTH: ENTER YEAR: | october 2017 | |
|--------------|--------------------|---------------|-----------|-----------------------------|------------------|--------------|
| 2017 | | | | | ENTER START DAY: | Sunday |
| | | | | Link to Ongoing Patients | i . | |
| Sunday | Monday | Tuesday | Wednesday | Thursday | Friday | Saturday |
| 01 | 02 | 03 | 03 04 | | 06 | 07 |
| | Smith, Jane: 12345 | | | | | doe,j: 12347 |
| | doc.john: 12348 | | | | | |
| | | | | | | |
| 08 | 09 | 10 | 11 | 12 | 13 | 14 |
| | | | | | smith,m: 123 | |
| | | | | | | |
| | | | | | | |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| smith,b: 111 | | smith,d: 1549 | | | | |
| | | | | | | |
| | | | | | | |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| 29 | 30 | 31 | | | | |
| | | | | | | |
| | | | | | | |

Navigating Insurance/Prior Authorizations

Comprehensive Visit Clinic Notes

Project ECHO

Recommended regimen

Lab Values

- Chem 14, CBC, anemia panel, Vit D, AFT, HIV, Hep A & B, pregnancy
- Viral load and genotype
- Fibrosis Score: APRI, FIB4, Fibrotest

Abstinence requirements

Urine drug screens and/or clinical notes

Compliance

Patient Assistance Program

Gilead's Support Path

- Harvoni®, Epclusa®
- iAssist: https://www.assistrx.com/iassist/


AbbVie Patient Assistance Foundation

•Mavyret®


Patient Assistance Programs

- Tribal ID card
- Income documents
 - Max income allowed differs by program
- Proof of no insurance
 - American Indians/AlaskaNatives (AI/AN): Indian HealthCoverage Exemption
- "American Indians and Alaska Natives (AI/ANs) and other people eligible for services through the Indian Health Service, tribal programs, or urban Indian programs (like the spouse or child of an eligible Indian) don't have to pay the fee for not having health coverage. This is called having an Indian health coverage exemption."

Time Investment and Workload (Minutes)




Current Status




Patients Enrolled in Clinic


AGE DISTRIBUTION




HCV Screening Rate



HCV Screening Rate



Cost Analysis: Cumulative



Next Steps

Leading efforts in the Great Plains, Bemidji and Billings Areas

> Sharing experiences and resources with other service

units



Next Steps



Success Story

ND Medicaid and Expansion





Drop minimum fibrosure score requirements






12-months abstinence requirements remains



No NS5A resistance test required unless prescribing Zepatier®

Medicaid Letter - Balancing Act



Hepatitis Listserv

Share info via text HCV to 97779 Create a NICE Project Listserv to continuously improve and grow resources

Create a MAX.gov to share resources

Patient's Story

First patient enrolled in HCV clinic summer of 2017, achieved SVR mid-November

"I have been waiting for this for so long. I know I have made some mistakes in the past, but I had started to turn my life around. I am very thankful to them for not being judgmental and for treating me with respect. I am finally able to start a family. God bless you!"

- First patient to attain SVR in HCV clinic

Recorded Webinars

- http://www.npaihb.org/hcv/#clinical-resources
 - ► How to create an iCare panel
 - ► How to create a quick order menu for required labs
 - ► How to use the NICE patient management tool
 - Hepatitis C clinic workflow
 - ► Medicaid Letter, appointment cards



Special Thanks

- Jessica Leston, HCV/HIV/STI Clinical Programs Director for the Northwest Portland Area Indian Health Board
- Brigg Reilley, National HIV/AIDS Program
- David Stephens, BSN, RN, Case Manager for the Northwest Portland Area Indian Health Board.

Questions



Thank you

Contact Info:

Neelam.Gazarian@ihs.gov

Jonathan.Owen@ihs.gov

701-477-6111 Ext 8426